GlobeNewswire: CytoDyn Inc. Contains the last 10 of 362 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T05:01:30ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/02/29/2837977/0/en/CytoDyn-Announces-FDA-Has-Lifted-Clinical-Hold.html?f=22&fvtc=4&fvtv=14974CytoDyn Announces FDA Has Lifted Clinical Hold2024-02-29T13:30:00Z<![CDATA[Webcast to Provide Company Update on March 5, 2024]]>https://www.globenewswire.com/news-release/2024/02/01/2821970/0/en/CytoDyn-Announces-Submission-of-Clinical-Protocol-to-FDA-and-Initiation-of-Pre-Clinical-Study-in-Glioblastoma.html?f=22&fvtc=4&fvtv=14974CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma2024-02-01T13:30:00Z<![CDATA[VANCOUVER, Washington, Feb. 01, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the Company has submitted its revised HIV clinical trial protocol to the FDA. The Company believes this submission will lead to the removal of the clinical hold currently in effect.]]>https://www.globenewswire.com/news-release/2024/01/29/2818905/0/en/CytoDyn-Appoints-Jacob-Lalezari-M-D-as-CEO-Mitchell-Cohen-as-Interim-CFO.html?f=22&fvtc=4&fvtv=14974CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO2024-01-29T13:30:00Z<![CDATA[VANCOUVER, Washington, Jan. 29, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob Lalezari, formerly interim CEO, was appointed to the CEO role, effective January 26, 2024.]]>https://www.globenewswire.com/news-release/2023/12/07/2792878/0/en/CytoDyn-Announces-Webcast-to-Provide-Company-Update.html?f=22&fvtc=4&fvtv=14974CytoDyn Announces Webcast to Provide Company Update2023-12-07T21:00:43Z<![CDATA[VANCOUVER, Washington, Dec. 07, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, interim Chief Executive Officer, will host an investment community webcast to provide a Company update on Thursday, December 14, 2023. The Company update will include discussion about recent comments from the FDA concerning the clinical hold, an anticipated timeline to respond to the FDA and resolve the clinical hold, the Company’s next proposed clinical trial, the current approach to business development opportunities, and overall development strategy.]]>https://www.globenewswire.com/news-release/2023/11/21/2784054/0/en/CytoDyn-Appoints-Jacob-Lalezari-M-D-as-Interim-CEO.html?f=22&fvtc=4&fvtv=14974CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO2023-11-21T13:30:00Z<![CDATA[VANCOUVER, Washington, Nov. 21, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the appointment of Dr. Jacob Lalezari as interim CEO, effective November 17, 2023. Dr. Lalezari will be responsible for leading the Company’s corporate and product development, with a focus on short-term clinical development and related fundraising. Antonio Migliarese, who had been serving as interim president since May 2023, in addition to CFO, will resume his previous role as CFO.]]>https://www.globenewswire.com/news-release/2023/11/03/2773434/0/en/November-2023-Letter-to-Shareholders.html?f=22&fvtc=4&fvtv=14974November 2023 Letter to Shareholders2023-11-03T20:02:25Z<![CDATA[VANCOUVER, Washington, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Dear Shareholders,]]>https://www.globenewswire.com/news-release/2023/07/11/2703127/0/en/CytoDyn-Announces-Company-Updates-and-Investment-Community-Update-Webcast.html?f=22&fvtc=4&fvtv=14974CytoDyn Announces Company Updates and Investment Community Update Webcast2023-07-11T20:05:00Z<![CDATA[Claim Filed in Former CRO Litigation for Damages Exceeding $100M]]>https://www.globenewswire.com/news-release/2023/05/24/2675727/0/en/CytoDyn-Announces-President-Takes-Medical-Leave-of-Absence.html?f=22&fvtc=4&fvtv=14974CytoDyn Announces President Takes Medical Leave of Absence2023-05-24T21:05:07Z<![CDATA[Antonio Migliarese assumes interim President roleDr. Melissa Palmer appointed interim Chief Medical OfficerDr. Salah Kivlighn joins CytoDyn as clinical and strategic advisor]]>https://www.globenewswire.com/news-release/2023/04/05/2641690/0/en/CytoDyn-to-Hold-Webcast-to-Provide-a-Company-Update.html?f=22&fvtc=4&fvtv=14974CytoDyn to Hold Webcast to Provide a Company Update2023-04-05T12:30:52Z<![CDATA[VANCOUVER, Washington, April 05, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Tanya Urbach, Board Chair, Cyrus Arman, President, Antonio Migliarese, Chief Financial Officer, and Scott Hansen, our newly appointed Head of Research and Basic Science, will host an investment community webcast to provide a Company update on Tuesday, April 11, 2023.]]>https://www.globenewswire.com/news-release/2022/12/23/2579117/0/en/CytoDyn-to-Hold-Webcast-to-Discuss-the-Performance-of-Leronlimab-in-Clinical-Trials-and-Recent-Charges-Against-Former-CEO.html?f=22&fvtc=4&fvtv=14974CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO2022-12-23T13:00:10Z<![CDATA[VANCOUVER, Washington, Dec. 23, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, will hold a webcast on December 29, 2022 at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) to discuss the performance of leronlimab in its clinical trials and the recent charges against its former CEO Nader Pourhassan, who was previously terminated on January 24, 2022, and has had no affiliation with the Company since that time.]]>